Stockscreener 앱 받기
16.67
4.58%
-0.80
시장 영업 전:
16.67
Korro Bio Inc 주식(KRRO)의 최신 뉴스
Cantor Fitzgerald sets $74 target on Korro Bio stock with Overweight rating - Investing.com
Korro Bio (NASDAQ:KRRO) Research Coverage Started at Chardan Capital - Defense World
Chardan sets $25 target on Korro Bio stock with Buy rating - Investing.com Australia
Chardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - Nasdaq
Chardan Initiates Korro Bio at Buy With $25 Price Target - marketscreener.com
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by Wellington Management Group LLP - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Buy” by Brokerages - Defense World
KLP Kapitalforvaltning AS Purchases New Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Kemi Olugemo '87 Named Chief Medical Officer at Korro Bio - UMass Lowell
Raymond James Financial Inc. Purchases New Shares in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio appoints new Chief Scientific Officer By Investing.com - Investing.com South Africa
Korro Appoints Loïc Vincent, Ph.D., as Chief Scientific Officer - citybiz
Korro Bio appoints new Chief Scientific Officer - Investing.com
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - The Manila Times
RNA-Editing Pioneer Korro Bio Lands Elite CSO with 20+ Drug Development Success Record - Stock Titan
Swiss National Bank Acquires Shares of 10,000 Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha
Korro Bio reappoints CFO, names new principal accounting officer By Investing.com - Investing.com Canada
Korro Bio CFO Returns from Medical Leave - TipRanks
Korro Bio reappoints CFO, names new principal accounting officer - Investing.com
Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO - MarketScreener
HC Wainwright Has Negative Outlook for Korro Bio Q1 Earnings - The AM Reporter
Research Analysts Set Expectations for Korro Bio Q1 Earnings - Defense World
Korro Bio (KRRO) Gets a Buy from Piper Sandler - The Globe and Mail
Q1 Earnings Forecast for Korro Bio Issued By William Blair - Armenian Reporter
HC Wainwright Reiterates Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Q1 Earnings Estimate for Korro Bio Issued By William Blair - Defense World
Royal Bank of Canada Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price - Defense World
Korro Bio Reports 2024 Financial Results and Progress - TipRanks
H.C. Wainwright maintains Buy rating on Korro Bio stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy rating on Korro Bio stock - Investing.com
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth - Investing.com Australia
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth By Investing.com - Investing.com South Africa
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Yahoo
RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk - Marketscreener.com
Korro Bio, Inc. SEC 10-K Report - TradingView
Korro Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Korro Bio Reports Clean Safety Data in AATD Drug Trial, Secures $163M Runway - StockTitan
Korro Bio (KRRO) Projected to Post Earnings on Tuesday - Defense World
FDA grants orphan drug status to Korro’s AATD treatment By Investing.com - Investing.com Australia
Korro Bio gets FDA Orphan Drug tag (KRRO:NASDAQ) - Seeking Alpha
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation - Marketscreener.com
FDA grants orphan drug status to Korro’s AATD treatment - Investing.com
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - The Manila Times
Breakthrough for Rare Disease: FDA Awards Special Status to Korro Bio's Novel RNA Treatment - StockTitan
Rhumbline Advisers Purchases 691 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
0.78%
2.03%
자본화:
|
볼륨(24시간):